GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

In the June issue of the journal Cell Stem Cell, a team of scientists reported success in what may be the first documented rescue of a congenital brain disorder by transplantation of human neural stem cells. The researchers developed a new transplant procedure that resulted in infiltration of human glial progenitor cells throughout the brain and spinal cord of "shiverer mice." The engrafted mice exhibited robust, efficient, and functional myelination, according to the scientists.


During this week's GEN podcast, research team member Dr. Steven Goldman, from the University of Rochester Medical Center, discusses the purpose of the experiment and the final results. He also explains how his team's studies differ from other research that focuses on remylineating nerve cells. Regarding the group's novel cell delivery strategy, Dr. Goldman describes the approach in detail as well as its advantages over other cell delivery methods.


Dr. Goldman is internationally recognized for advancing our understanding of stem cells and their use to treat human disease. He began his studies of the brain’s stem cells more than 25 years ago, and his doctoral thesis in 1983 was the first report of neurogenesis - the production of new brain cells - in the adult brain and opened the door to the idea of neural stem cells as the source. He has created new ways to isolate stem cells and then re-create the molecular signals that direct their development. In his laboratory, work is underway on cancer, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis (ALS), spinal cord injury, multiple sclerosis, and fatal children’s diseases known as pediatric leukodystrophies. The research is supported by more than two dozen organizations around the globe. A native of Philadelphia, Goldman earned his bachelor’s degree at the University of Pennsylvania, his Ph.D. at Rockefeller University, and his M.D. at Cornell University. He served on the faculty at Cornell University Medical College for 15 years before joining the University of Rochester in 2003.

Add a comment

  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?